T cells expressing CD26-specific chimeric antigen receptors exhibit extensive self-antigen-driven fratricide.
Conclusion: Eradicating CML-LSCs via anti-CD26-4-1BB-CAR T cells is not applicable, and optimized design or alternative target is needed.
PMID: 31303072 [PubMed - as supplied by publisher]
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Genetics | Hematology | Immunotherapy | Leukemia | Stem Cell Therapy | Stem Cells